Sponsor hub
Gilead Sciences clinical trial failures
Review 110 stopped clinical trials from Gilead Sciences, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 25 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OTHER/UNKNOWN
- 49
- OPERATIONAL
- 36
- EFFICACY/FUTILITY
- 16
- SAFETY
- 9
Notable sponsors
- Gilead Sciences
- 110
Related phases
- Phase II
- 46
- Phase I
- 38
- Phase III
- 24
- Phase IV
- 2
Crawlable stopped-trial records
Open ExploreShowing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase II RSV Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated by Sponsor; the decision was not due to any safety findings.
Phase II RSV Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated by Sponsor; the decision was not due to any safety findings.
Phase I Rheumatoid Arthritis trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study terminated due to lack of efficacy.
Phase II HIV-1-infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study.
Phase II Filovirus Disease trial by Gilead Sciences. Stop reason: OPERATIONAL.
The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.
Phase II Cutaneous Lupus Erythematosus (CLE) trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor Decision
Phase II Head and Neck Squamous Cell Carcinoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study
Phase II Triple-Negative Breast Cancer trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study.
Phase I HIV-1-infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study.
Phase II Metastatic Colorectal Cancer trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study
Phase I B-cell Malignancies trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.
Phase I Non Hodgkin Lymphoma trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Study terminated early due to the magrolimab program discontinuation.
Phase II Solid Tumor trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study
Phase II Multiple Myeloma trial by Gilead Sciences. Stop reason: OPERATIONAL.
This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.
Phase III Acute Myeloid Leukemia trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study was terminated due to futility
Phase II Myeloid Malignancies trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate the study.
Phase II Primary Biliary Cirrhosis (PBC) trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.
Phase III Acute Myeloid Leukemia trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study discontinued due to futility.
Phase II COVID-19 trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated by Sponsor; the decision was not due to any safety findings.
Phase I Hematological Malignancies trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.
Phase II Primary Sclerosing Cholangitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Study was terminated as a precautionary measure due to histological findings in a nonalcoholic steatohepatitis (NASH) study (CB8025-21730, NCT03551522).
Phase III COVID-19 trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.
Phase I Human Immunodeficiency Virus Type 1 (HIV-1) Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.
Phase I Advanced Solid Tumors trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583.
Phase III Myelodysplastic Syndromes trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study discontinued due to futility based on a planned analysis
Phase I Cutaneous Lupus Erythematosus trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to terminate study.
Phase I Metastatic Colorectal Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase III Primary Sclerosing Cholangitis trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.
Phase I Advanced Solid Tumors trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
The decision to discontinue the study was made based on the totality of the clinical, pharmacokinetic, and pharmacodynamic findings. No safety concerns were observed.
Phase III Follicular Lymphoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
Gilead has made the decision to close the study due to enrollment challenges
Phase I Primary Sclerosing Cholangitis trial by Gilead Sciences. Stop reason: OPERATIONAL.
The study enrollment was terminated early by the sponsor due to recruitment challenges.
Phase I Non-hodgkin Lymphoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor's decision to discontinue development of this molecule
Phase III COVID-19 trial by Gilead Sciences. Stop reason: OPERATIONAL.
The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns.
Phase I Advanced Solid Tumors trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Gilead decision to terminate
Phase II NASH - Nonalcoholic Steatohepatitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
unexpected histological findings
Phase II Ulcerative Colitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Sponsor terminated the study since a new molecular entity was able to achieve greater target coverage
Phase III Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.
Phase II Rheumatoid Arthritis trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor decision to withdraw study.
Phase III Psoriatic Arthritis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase II Chronic Hepatitis B trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated due to sponsor's decision to not pursue further development of inarigivir soproxil in chronic hepatitis B.
Phase III Psoriatic Arthritis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase II Noninfectious Uveitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase III COVID-19 trial by Gilead Sciences. Stop reason: OPERATIONAL.
The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.
Phase I Non-Hodgkin's Lymphoma trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study was terminated due to lack of efficacy, as a result, the stability program for the drug product was discontinued
Phase II Metastatic Colorectal Cancer trial by Gilead Sciences. Stop reason: OPERATIONAL.
No participants enrolled
Phase I GVHD (Acute or Chronic) trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled
Phase I Colorectal Neoplasms trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Triple-negative Breast Cancer trial by Gilead Sciences. Stop reason: OPERATIONAL.
FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated
Phase I Non-hodgkin's Lymphoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was stopped due to insufficient efficacy and very slow accrual
Phase II Waldenstrom Macroglobulinemia trial by Gilead Sciences. Stop reason: OPERATIONAL.
low accrual
Phase I Metastatic Pancreatic Adenocarcinoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
no subjects enrolled
Phase I Non Hodgkin's Lymphoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
No subjects enrolled
Phase I Non-Hodgkins Lymphoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
lack of accrual
Phase III Metastatic Pancreatic Cancer trial by Gilead Sciences. Stop reason: SAFETY.
The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm did not demonstrate a sufficient improvement in OS vs. placebo.
Phase I Multiple Myeloma trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
Study was terminated due to lack of efficacy
Phase I Metastatic Colorectal Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
A new study is being designed. No patients were enrolled.
Phase I Purpura, Thrombocytopenic, Idiopathic trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Spontaneous Urticaria trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase I Previously Untreated Pancreatic Ductal Adenocarcinoma trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Ankylosing Spondylitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase III Ankylosing Spondylitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Development program terminated
Phase II HIV-1-infection trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
GS-9131 did not meet the targeted antiviral response
Phase I Gastric Adenocarcinoma trial by Gilead Sciences. Stop reason: OPERATIONAL.
Study was terminated due to sponsor's decision to not pursue further development of andecaliximab in oncology
Phase I Metastatic Castrate-Resistant Prostate Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Chronic Lymphocytic Leukemia (CLL) trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: OPERATIONAL.
Sponsor's decision to discontinue development of entospletinib.
Phase II Hepatitis C Virus Infection trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
SOF/VEL/VOX will not be evaluated in younger age groups.
Phase II Primary Biliary Cholangitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
The study was terminated because of the availability of alternate therapies for primary biliary cholangitis (PBC).
Phase I Myelofibrosis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Nonalcoholic Steatohepatitis trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
Phase II Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: SAFETY.
Study was terminated due to safety measures.
Phase III Nonalcoholic Steatohepatitis trial by Gilead Sciences. Stop reason: EFFICACY/FUTILITY.
This study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.
Phase I Hematologic Malignancy trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No signal of efficacy with Entospletinib
Phase IV Lymphoid Malignancies trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Acute Lymphoblastic Leukemia trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Acute Myeloid Leukemia trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase III Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Advanced Estrogen Receptor Positive HER2- Breast Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Hepatitis B trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Follicular Lymphoma trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase II Crohn's Disease trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Non-Hodgkin Lymphoma trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Colorectal Cancer trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Ulcerative Colitis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Liver Fibrosis Due to NASH trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Liver Fibrosis Due to NASH trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Chronic Graft Versus Host Disease trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase I Diffuse Large B-Cell Lymphoma trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics
Phase III Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase II B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase III Chronic Lymphocytic Leukemia trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase II Chronic Lymphocytic Leukemia (CLL) trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Hepatitis C Virus Infection trial by Gilead Sciences. Stop reason: OPERATIONAL.
Due to lack of feasibility of enrolling participants, the study was terminated early.
Phase III Indolent Non-Hodgkin's Lymphomas trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase III Indolent Non-Hodgkin's Lymphomas trial by Gilead Sciences. Stop reason: SAFETY.
No stop-reason text available in the compact dataset.
Phase II Hypertrophic Cardiomyopathy trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase II Cystic Fibrosis trial by Gilead Sciences. Stop reason: OTHER/UNKNOWN.
Discontinuation of development for this indication